Date:	15 December_2023	8
Your Name:	Fumihiro Kas	shizaki
Manuscript Title:	Effective Treatment of M	ET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib
Following Serious I	Maculopapular Rash Cause	ed by Two MET-inhibitors: A Case Report
Manuscript numb	oer (if known): AC	R-23-181

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial    X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	15 December_202	23
Your Name:	Shunsuke (	Dkazaki
Manuscript Title	Effective Treatment of	MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib
Following Serious	Maculopapular Rash Cau	used by Two MET-inhibitors: A Case Report
Manuscript num	ber (if known): A	CR-23-181

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial    X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	15 December_2023	3
Your Name:	Nanami Tsu	chiya
<b>Manuscript Title</b>	: Effective Treatment of M	IET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib
Following Serious	Maculopapular Rash Caus	sed by Two MET-inhibitors: A Case Report
Manuscript num	ber (if known): AC	CR-23-181

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial    X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	15 December_202	23
Your Name:	Hao Chen	
Manuscript Title	e: Effective Treatment of N	MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib
Following Serious	Maculopapular Rash Cau	used by Two MET-inhibitors: A Case Report
Manuscript num	nber (if known): A	CR-23-181

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial    X_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	15 December_2023		
Your Name:	Harumi Koizumi		
<b>Manuscript Titl</b>	e: Effective Treatment of MET E	xon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib	
Following Serious Maculopapular Rash Caused by Two MET-inhibitors: A Case Report			
Manuscript nur	mber (if known): ACR-23	.181	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial     X_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	XNone	

	5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<b>X</b> None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	15 December_2023	<u> </u>	
Your Name:	Kenichi Taka	hashi	
Manuscript Title:	Effective Treatment of M	ET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancer Using Capmatinib	
Following Serious Maculopapular Rash Caused by Two MET-inhibitors: A Case Report			
Manuscript num	per (if known): AC	R-23-181	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial    X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	
3	Royalties or licenses	_ <b>X</b> None	
4	Consulting fees	XNone	

	5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<b>X</b> None	
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<b>X</b> None	
13	Other financial or non- financial interests	XNone	

I have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: